The effect of nesiritide on renal function and other clinical parameters in patients with decompensated heart failure and preserved ejection fraction

Congestive Heart Failure, 04/26/2012

Nesiritide can be administered safely without negatively impacting long–term renal function in patients admitted with decompensated heart failure with preserved ejection fraction (dHFpEF).

Methods

  • In this investigation, the authors retrospectively analyzed the effect of nesiritide on renal function and clinical outcomes in patients admitted with dHFpEF.
  • Of the 658 patients included.
  • 328 were treated with nesiritide while 330 patients were treated with standard diuretic therapy.
  • In both the nesiritide and no nesiritide groups, there was a significant change in mean glomerular filtration rate (GFR) and creatinine at 72 hours as well as at day of discharge (P<.001).
  • This trend did not progress at 1 month in the nesiritide group, although it did in the no nesiritide group.

Results

  • At 1 month after therapy, however, there was a significant difference between the two groups in the mean change of GFR and creatinine (P<.001).
  • There was no significant difference in >25% decrease of GFR anytime through day 30 (25% vs 29.69%, P=.236) between the two groups.
  • On multivariate analysis, nesiritide was an important predictor of renal function at 1 month (P<.05).

Print Article Summary